Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · May 20, 2024

Real-World Data on the Prevalence of Treatment-Related Adverse Events and Reasons for Immunosuppressive Agent Discontinuation in Patients With Myasthenia Gravis

Neuromuscular Disorders


Additional Info

Neuromuscular Disorders
Mycophenolate and methotrexate are better tolerated than azathioprine in myasthenia gravis
Neuromuscul. Disord. 2024 May 01;38(1)51-57, KC Dodd, R Ahmed, P Ambrose, JK Holt, S Jacob, MI Leite, JA Miller, PP San, J Spillane, S Viegas, J Sussman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading